Drug Trial Radar · NCT00323102
A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain
Last checked: Nov 19, 2026Latest source record: Jan 23, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
114
Actual
Start
May 2006
Primary completion
Not stated
Study completion Mar 2007
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication
Conditions
- Brain Pathology
Interventions
MultihanceDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Superiority of Multihance in terms of by-patient global diagnostic performanceTime frame: immediately post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bracco Diagnostics, Inc.
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.